Trial Profile
A Phase 3, Randomized, Double-blind, Active-controlled Study to Evaluate the Effects of Bexagliflozin versus Glimepiride in Subjects with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control by Metformin.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Dec 2022
Price :
$35
*
At a glance
- Drugs Bexagliflozin (Primary) ; Glimepiride
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Theracos
- 26 Dec 2022 Results assessing the effects of bexagliflozin tablets 20 mg, with those of optimally titrated glimepiride when used to treat adults with type 2 diabetes mellitus (T2DM) inadequately controlled by metforminpublished in the Diabetes, Obesity and Metabolism
- 06 Aug 2019 Status changed from active, no longer recruiting to completed.
- 14 Jul 2019 This trial has been completed in Spain.